Molina Healthcare Slides 39.5% as Medicaid and Medicare Cost Pressures Outpace Revenue, Stock Ranks 435th in Trading Volume

Generated by AI AgentAinvest Volume Radar
Thursday, Aug 28, 2025 6:42 pm ET1min read
Aime RobotAime Summary

- Molina Healthcare (MOH) fell 39.5% YTD in 2025, underperforming the S&P 500 and healthcare ETF due to Medicaid/Medicare cost pressures exceeding revenue growth.

- Q2 2025 revenue rose 15.7% to $11.4B, but adjusted EPS dropped 6.5%, triggering a 17% post-earnings selloff and analyst downgrades to "Hold" from "Moderate Buy."

- Analysts set a $194.07 average price target (10.2% upside), with Cantor Fitzgerald citing Florida operational risks and a $284 peak target indicating 61.3% potential gains.

On August 28, 2025,

(MOH) closed down 0.79%, with a trading volume ranking of 435 among listed stocks. The stock has underperformed year-to-date, falling 39.5%, compared to a 10.2% gain in the S&P 500 and a 9% rise in the SPDR Health Care Services ETF (XHS). This decline reflects heightened medical cost pressures in Medicaid, Medicare, and ACA Marketplace segments, which have outpaced revenue growth. In Q2 2025, reported $11.4 billion in revenue, up 15.7% YoY, but adjusted EPS dropped 6.5% to $5.48, leading to a 17% post-earnings selloff.

Analysts have downgraded their outlook, with a “Hold” consensus rating, down from “Moderate Buy.” Of 17 analysts, four maintain a “Strong Buy,” 11 a “Hold,” and one each a “Moderate Sell” and “Strong Sell.”

Fitzgerald reaffirmed a $210 price target but cited concerns over Florida operations in 2026. The mean price target of $194.07 implies a 10.2% upside from current levels, while the highest target of $284 suggests a 61.3% potential gain.

Query limit exceeded.

Comments



Add a public comment...
No comments

No comments yet